Literature DB >> 27460987

GLIPR1 inhibits the proliferation and induces the differentiation of cancer-initiating cells by regulating miR-16 in osteosarcoma.

Jian Dong1, Binna Bi1, Lianhai Zhang2, Kaituo Gao1.   

Abstract

Osteosarcoma is a common, highly malignant and metastatic bone cancer. Elucidation of the molecular mechanisms of osteosarcoma may further help us to understand the pathogenesis of the disease, and offer novel targets for effective therapies. Human glioma pathogenesis-related protein 1 (GLIPR1) has been found to be downregulated in human cancers. However, its roles have not been reported in osteosarcoma. In the present study, we demonstrated that GLIPR1 protein was downregulated in osteosarcoma. Its overexpression inhibited the proliferation, migration and invasion and induced the differentiation of cancer-initiating cells (CICs) in osteosarcoma. Moreover, GLIPR1 overexpression upregulated miR-16 in osteosarcoma cells. The upregulation suppressed proliferation, migration and invasion as well as induced differentiation of CICs in osteosarcoma. Thus, we conclude that GLIPR1 inhibited the proliferation, migration and invasion and induced the differentiation of CICs by regulating miR-16 in osteosarcoma. The present study provides direct evidence that GLIPR1 is a bona fide tumor suppressor and identified GLIPR1 and miR-16 as key components for regulating the proliferation, migration, invasion and CICs in osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27460987     DOI: 10.3892/or.2016.4949

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

2.  GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway.

Authors:  Yuen Chak Tiu; Lanqi Gong; Yu Zhang; Jie Luo; Yuma Yang; Ying Tang; Wing-Mui Lee; Xin-Yuan Guan
Journal:  Cancer Gene Ther       Date:  2022-06-27       Impact factor: 5.987

Review 3.  Glioma pathogenesis-related protein 1 performs dual functions in tumor cells.

Authors:  Junjie Wang; Zeyu Li; Fenfen Yin; Rui Zhang; Ying Zhang; Zhengxin Wang; Xiumei Sheng
Journal:  Cancer Gene Ther       Date:  2021-03-19       Impact factor: 5.987

4.  GliPR1 knockdown by RNA interference exerts anti-glioma effects in vitro and in vivo.

Authors:  Urban J Scheuring; Steffi Ritter; Daniel Martin; Gabriele Schackert; Achim Temme; Stefanie Tietze
Journal:  J Neurooncol       Date:  2021-04-15       Impact factor: 4.130

5.  GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice.

Authors:  Natasha Friend; Jacqueline E Noll; Khatora S Opperman; Kimberley C Clark; Krzysztof M Mrozik; Kate Vandyke; Duncan R Hewett; Andrew C W Zannettino
Journal:  PLoS One       Date:  2020-01-29       Impact factor: 3.240

6.  Expression and Genetic Effects of GLI Pathogenesis-Related 1 Gene on Backfat Thickness in Pigs.

Authors:  Xin Liu; Hanmei Li; Longchao Zhang; Ligang Wang; Lixian Wang
Journal:  Genes (Basel)       Date:  2022-08-14       Impact factor: 4.141

7.  Key genes and drug delivery systems to improve the efficiency of chemotherapy.

Authors:  Zally Torres-Martinez; Yamixa Delgado; Yancy Ferrer-Acosta; Ivette J Suarez-Arroyo; Freisa M Joaquín-Ovalle; Louis J Delinois; Kai Griebenow
Journal:  Cancer Drug Resist       Date:  2021-03-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.